A comparative histopathological remedial study of polyherbal formulation Diabcure and Glibenclamide on Streptozotocin induced diabetic rats

Abstract

Diabetes mellitus is one of the most important health problems worldwide, showing high indices of prevalence and mortality. It is also rapidly emerging as a major health-care problem in India, especially in urban areas where the prevalence of Type 2 diabetes has been reported as 12% of the adult population. A histopathological study was carried out on wistar rat in which comparative remedial effectiveness was studied of 2 different medicines Diabcure and Glibenclamide. The rats were divided into 4 groups with 6 rats in each group and were treated accordingly Group 1: Control rats given physiological saline solution 10mL/Kg body wt, Group 2: Rats injected Streptozotocin (45mg/kg ip body wt.) intraperitonially, Group 3: Rats injected Streptozotocin (45 mg/kg ip body wt.) intraperitonially + Polyherbal Formulation Diabcure (PHFD) (125 mg/kg body wt.) administered orally using an intragastric tube. Group 4: Rats injected (45 mg/kg ip body wt.) intraperitonially + Glibenclamide (125mg/kg body wt.) administered orally using an intragastric tube. After 30 days of the treatment the rats were sacrificed and blood glucose level was determined along with the histopathological study of the liver, pancreas and kidney was carried out. Histopathological changes were observed in Streptozotocin treated rats showed fatty changes, necrosis, vacuolization, space formation and loss of cell boundaries in liver, proximal tubular necrosis, tubular degeneration and glomerular swelling in kidney and reduced islet cells and necrosis of pancreas. Oral administration of aqueous extract of Polyherbal Formulation Diabcure (PHFD) (125 mg/kg body weight) and Glibenclamide to Streptozotocin treated rats brought back the above-mentioned changes to near normal. But the histopathological study revealed that Diabcure was more effective then Glibenclamide.